PDB23 Budget Impact Analysis of the Reimbursement of Long-Acting Insulin Analogues in Poland

Value in Health - United Kingdom
doi 10.1016/j.jval.2011.08.1326
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Budget Impact of Long-Acting Insulin Analogues: The Case in Brazil

PLoS ONE
Multidisciplinary
2016English

Prs73 - The Budget Impact of Nicotinic Substitute Reimbursement

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Budget Impact Analysis of the New Reimbursement Policy for Day Surgery in Thailand

Risk Management and Healthcare Policy
Health PolicyPublic HealthOccupational HealthEnvironmental
2019English

Solution Structures of Long-Acting Insulin Analogues and Their Complexes With Albumin

2019English

Prescription Patterns of Long-Acting Somatostatin Analogues

SAGE Open Medicine
Medicine
2017English

Rapid-Acting Insulin Analogues Versus Regular Human Insulin: A Meta-Analysis of Effects on Glycemic Control in Patients With Diabetes

Diabetes Therapy
Internal MedicineEndocrinologyMetabolismDiabetes
2019English

Pmh23 - Real-World Costs and Budget Impact of Long-Acting Injection Atypical Antipsychotics for the Management of Schizophrenia in France

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Long Acting Insulin Glargine Overdose, a Surprising Long Lifetime

Toxicology Communications
2019English

Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-Long-Acting Basal Insulin

Pharmaceutical Research
Organic ChemistryBiotechnologyMolecular MedicinePharmacologyPharmaceutical Science
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy